Education
About Us
Working with TipRanks
Follow Us
Alvotech (ALVO)
NASDAQ:ALVO
ALVO Stock Chart & Stats
$4.64
$0.06(0.46%)
At close: 4:00 PM EST
$4.64
$0.06(0.46%)
Day’s Range― - ―
52-Week Range$4.32 - $12.89
Previous CloseN/A
Volume41.59K
Average Volume (3M)362.18K
Market Cap
$1.39B
Enterprise Value$2.69B
Total Cash (Recent Filing)$42.85M
Total Debt (Recent Filing)$1.28B
Price to Earnings (P/E)20.1
Beta0.84
Next Earnings
Mar 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding298,922,700
10 Day Avg. Volume398,563
30 Day Avg. Volume362,180
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-8.59
Price to Sales (P/S)7.24
P/FCF Ratio-12.06
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue4.70
Enterprise Value/Gross Profit8.48
Enterprise Value/Ebitda36.95
Forecast
1Y Price Target
$8.33Price Target Upside79.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
European Product ApprovalsRegulatory approval of AVT03 in the EEA converts R&D into a marketed product, expanding Alvotech's commercial portfolio. This durable revenue stream supports long-term market penetration in osteoporosis/oncology segments and strengthens payer relationships across Europe.
Secured U.S. Launch PathwayThe settlement with Regeneron clarifies AVT06 U.S. market timing, materially reducing litigation and exclusivity uncertainty. A definable U.S. entry date preserves partner economics with Teva and enables durable commercial planning in a high‑value retinal disease market.
Scale Investments And CapacityHeavy capital investment and targeted acquisitions build large-scale biomanufacturing capability, a structural advantage for biosimilars. Durable capacity and vertical integration support multiple global launches, lower per-unit costs, and sustained competitiveness over coming years.
Bears Say
High Financial LeveragePersistent negative equity and extreme leverage constrain financial flexibility, increasing refinancing and solvency risk. Over a multi‑month horizon this limits ability to absorb setbacks, forces engagement with costly debt markets, and can constrain strategic investments.
Weak Operating Cash FlowOngoing negative operating cash flow means launches and R&D rely on external financing rather than internal generation. This structural cash shortfall increases vulnerability to higher funding costs and can restrict long‑term reinvestment or dampen margins if financing tightens.
Regulatory/manufacturing RiskA CRL tied to manufacturing deficiencies imposes durable execution risk: remediation requires capital, time, and process changes, delaying launches and revenue. Recurrent facility issues can erode partner confidence and increase ongoing compliance costs and timeline uncertainty.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $4.32 and its highest was $12.89 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.39B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Mar 18, 2026 which is in 30 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.073.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is >-0.01.
How many shares outstanding does Alvotech have?
Alvotech has 298,922,700 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.33 (79.53% Upside)
$8.33 (79.53% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 344.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.29%
Trailing 12-Months
Company Description
Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company with strong growth and strategic investments, but it is facing significant regulatory and operational challenges that have impacted its short-term financial outlook.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$8.33
▲(79.53% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.60% Mutual Funds
0.04% Other Institutional Investors
97.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---